7/21/2019 Atencion_farmaceutica

1/13

TENCION

F RM CEUTIC

7/21/2019 Atencion_farmaceutica

2/13

EVALUACION FINAL DE ATENCION FARMACEUTICA

PRESENTADO POROFIR JIMENEZ PINILLA COD. 28817170

EGNA CORTES MALAVER COD. 65712728LUZ ESTELLA SALCEDO COD. 37555678

CRISTIAN MANUEL VILLAREAL COD.1082908127WALTER OLA!O

TUTORA

CLAUDIA GONZALEZ

UNIVERSIDAD NACIONAL AIERTA " ADISTANCIAFEC#A 20$12$201%

7/21/2019 Atencion_farmaceutica

3/13

INTRODUCCION

E&'( ')*+*,- -& /()'( --() -- 4'4)-& )(('(& (

*)** 4( & &( -& /)(&('* 4 /)-+(* )(*-*- - *

&'4* ( ** *&')* ( &'-: ( (*('- ( *

/-+* P*- -'*.

L*& )(-(*-(& 4( &( (+( ;*() (& 4 *(4*-

-)(*('- ( -& (*('-& ( * 4* ( &*4 - -+)(= -(')*-=+4( (&'*-= >?**&')*= (;* ( >(('- < 4 -))('- (&/*;-

4'@*- 4 )(&')- ( -&4- < (&'(* ( -& (*('-&.

7/21/2019 Atencion_farmaceutica

4/13

SITUACION PROBLEMA

L* P-+* ( P*- -'- &( (4(')* &'4** ( 4* )( ( *B- ;(- - '(/()*'4)* *+('( 4( -&* (')( 25 * 30 C - *)*4'- 4('* - 4 )(('( ( *)**< 4 '- /)-(&-* ( ( &()>- *)*4'-&.

E ( &()>- *)*4'- &( (&*))-* -& /)-(&-& (()*(&(&'*+(-& /-) * -)*'>*.

P*)* ( /)-(&- ( &')+4 '()* &( *'(( *& ((&*(&&4-& ( ()('(& &()>-& *(,*- ( '-- /-) &'-:.

E ?*& /*&*-& 4)*'( 4* >&'* ( &/( < -')- * &'-: (4)(*& ( R(('( ( F*)** (-') 4* &()( ( -&&'(*&

7/21/2019 Atencion_farmaceutica

5/13

4( ( ;* /4(&'- * /(&*) * ((&* ( (&'*+(() 4 /* ((,-)* /*)* * *'( /-) /*)'( ( &()>- *)*4'-.

L*& -&&'(*& (-')**& 4()-H

V*)-& (*('-& >(-& < -')-& - (;*& 4< /)*& *>(().

M(*('-& 4( - /()'((( * &'-:

C*'*(& ( (*('-& &4/()-)(& * *& *4'-)@**&.

E))-)(& ( * 4+* ( -& (*('-&H */-*& ( -)4)-

( &-- 4+**& ( *& ( -)4)- ( /-'*&-. D(&*'4*@* ( *4* ( /)-(('-& /*)* * )(/-&( &'-:.

E ;-&/'* >(( ')*+*,*- *)4*('( /*)* *) 4/('- * -&)(4&'-& ( ;*+'* &( * -)*'>* >('(. P-) - 4((& /)-)'*)- /*)* ( )(('( ( R(('( /)(&('*) < *) - * 4

/* ( (,-)* 4( (& /()'* (&*))-*) 4 *(4*- /)-(&- (&')+4 /-) &'-: /*)* ( &()>- ( 4)(*&.

7/21/2019 Atencion_farmaceutica

6/13

ALTERNATIVAS DE SOLUCION

V*)-& (*('-& >(-& < -')-& - (;* 4< /)* *>(().

E&'( ;**@- &( * /-)4( - &( )(*@* 4 (+- /)-(&- (**(*('- < -')- ( -& >('*)-& ( ** (/((*.

E&'- /4(( (,-)*) /)-->(- * ->@* ( -&(*('-& - (;* ( >(('- /)*= '*(& -- *

')*&()(* ( /)-4'-& * -')-& ;-&/'*(&= (')- ( 4 *)-*(4*- ( '(/- /*)* -)*) * 4'@* < 4*- (&'- - &(*/-&+(= (+( (*+-)*)&( 4 >('*)- )(4('(('( /*)* (>'*)(&'( '/- ( ;(;-&.

T*+ &( (+( --() * (* ( -&4- (&4* * **

(&/(** < '*+ -& B-& < ?-&= - ( (-&(4) 4* )-'* ( &'-: -/'*.

7/21/2019 Atencion_farmaceutica

7/13

M(*('-& 4( - /()'((( * &'-:.

S( (+( )(*@*) 4 &&'(* ( &')+4 < **(*('--))('*('(.

S( (+( '(() ( 4('* &-- -& (*('-& )(4()-& /-) (/()&-* ( (()()?* < &()>- *)*4'-.

R(*@* ( >('*)-& /()*('(.

C*'*(& ( (*('-& &4/()-)(& * *& *4'-)@**&.

E>'*) ( )(('- ( -&'-& /-)4( &( (&'B &-'*-*'*(& &4/()-)(& * *& )(4()*& - 4( /* 4( &((()( -&'-& *-*(& 4( /-)?* &() 4'@*-& ( -')-&(*('-& >'*(&.

T*+ &( /4(( -*) ( ( *4* ( /)-(&-& -&.

N- -4)&( /-) &4 /)(&('*.

C4*- 4 (*('- &(* 4'@*- (>*) * &'- -( - '--.

D(&*'4*@* ( *4* ( /)-(('-& /*)* * )(/-&( &'-:.

R(*@*)* < **@*) ( *4* ( /)-(&-& ( 4( &( (&'* **-4*- &( (&'* ;*(- * )(/-& ( &'-:.

I/(('*) 4(>-& '--& ( )(/-& ( &'-: --H D&')+4 +*&** ( )(/-& ( *'*(& ,**& ( 4&'*- (- * ** &()>- *&&'(* L* )(4(* ()(/-& (& ( ** 2% ;-)*& /-) ( &()>- *)*4'-.

C** &'-: (+( (&'*) *&*- * ,(( ( (()()?*. E )('-)'- ( &()>- *)*4'- )(*@* *4'-)*& * -& &'-: ('-& *>()&-& /4(( (>'*)&( & &( -))( (&'-&/)-+(*&.

U (>('- /)(>(+( /4(( (>'*)&( * < *)*'@* 4( -& (*('-& 4/* - '--& -&(&'B*)(& ( ** /*)* 4( ( /*('( '(* * &4 **(/)-4'-& 4( (,-)( &4 - ( >* < &*4.

7/21/2019 Atencion_farmaceutica

10/13

RECOMENDACIN

4( '-- &()>- *)*4'- '(* < */4( 4 *4* (/)-(&-& < /)-(('-& /*)* )(*@*) < 4/) &4& -+*-(&.

4( &( *-,* * * -)*'>* ** /-) * O)*@* M4* (* S*4.

C4/) * R(&-4 1%03 ( 2007.

7/21/2019 Atencion_farmaceutica

11/13

CONCLUCION

E& ( )* /-)'** -'*) - -& (*&-& ( -)* *(& -& /()'( (()*) 4* &()( (--('-& 4( -& /()')B ->()')-& ( 4-& +4(-&

/)-(&-*(& ( ( */- ( * F*)*4'*. N-& -'-)* ( (&'* *()* * -/-)'4* ( 4-& /)(4)&-)(& (

*& +4(*& /)*'*& ( **(*('-= &')+4 < &-+)( '--( 4?*& ( 4&- *(4*- ( -& (*('-&.

7/21/2019 Atencion_farmaceutica

12/13

BIBLIOGRAFA

R(&-4 1%03 ( 2007= '-*- (+)( 12 (201%=;''/H$$KKK.+.->.-$*)4(&$*>*($-$)(&-4-/)-'(-1%032007.;'

R(/-& ( &'-:= '-*- (+)( 12 (

201%=;''/H$$KKK.(.&./($/-)'*$-4('-&$/$-(&'-)(&-*4*$10082012MAPROLOGISALMADISTRI./

M4- A&')* ( S()>-& F*)*4'-&. T-*- (+)( 12 (201%=;''/H$$4*+.(4/-.-.-$/4(./;/$7208$-)(&-4)($-'('$1$UNID

AD520D&/(&*C3320-&

7/21/2019 Atencion_farmaceutica

13/13

GRACIAS